Kyndryl's price target was increased to $28/share by Scotiabank today. The current consensus 1 year analyst target is $26/share. After this price target upgrade, the consensus price target should increase to $26.75/share representing a 22% increase from the current price of $21.90/share.
The Morgan Stanley conference last week was just a reiteration of the current strategy and progress against the 3 "A" priorities. No new news was shared. The recording is on the company's website and worth listening to the webcast if you are new to the Kyndryl story.
I will be looking for additional coverage to be initiated over the next several quarters as the company moves towards profitability.
Comments